(as-PAYR-uh-jih-NAYS er-WIH-nee-uh krih-SAN-theh-my)
This page contains brief information about asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Asparaginase erwinia chrysanthemi (recombinant)-rywn is approved to treat adults and children aged 1 month and older with:
Asparaginase erwinia chrysanthemi (recombinant)-rywn is used in patients who can no longer take asparaginase made from E. coli. It is a recombinant form of asparaginase made from the bacterium Erwinia chrysanthemi.
This drug is also available in a non-recombinant form. For more information, see the Drug Information Summary for Asparaginase Erwinia Chrysanthemi.
More About Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Asparaginase erwinia chrysanthemi (recombinant)-rywn – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL
Clinical Trials Accepting Patients
Find Clinical Trials for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
